Deerfield Management

​​Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain’s tech-enabled services, outsourcing entire workflows to Ascertain’s team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain’s AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.

Nema Health is focused on delivering comprehensive trauma care through an online platform, specifically designed for individuals affected by post-traumatic stress disorder (PTSD). The company provides a virtual care center that enables trauma survivors to receive cognitive processing therapy from PTSD-trained therapists in the comfort and privacy of their homes. Nema Health's approach aims to offer effective and lasting relief for those dealing with the impacts of trauma.

Petfolk is a veterinary care provider that reimagines the traditional approach to pet healthcare by integrating in-person visits with virtual consultations. The company aims to enhance the communication between pet owners and veterinarians by offering a comprehensive range of services that cater to both scheduled on-site care and remote consultations. Petfolk emphasizes high-quality, accessible care delivered by a team of compassionate veterinarians, utilizing advanced technology to facilitate interactions. This model enables pet owners to strengthen their relationships with both their pets and the veterinary professionals who care for them.

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Relation Therapeutics is a biotechnology company that focuses on humanizing drug discovery and development. It leverages human genetics and clinical omics data and utilizes patient-derived tissue samples with functional genomics interventional experiments to identify, validate, and prosecute therapeutic programs.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Ray Therapeutics is a company that creates novel optogenetic gene therapies for patients with blinding diseases. The company develops technology to study and learn about rare retinal diseases, allowing doctors to cure and treat inherited retinal diseases using optogenetics.

Cortica Inc. is a healthcare company that specializes in providing neurological therapies for children with autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers a range of services including diagnoses for autism, ADHD, developmental delays, and other developmental differences. The company's treatment approach is tailored to each child, based on a comprehensive understanding of their neurobiology and developmental profile. Cortica provides customized treatment programs through in-home, in-clinic, and telehealth services. Its offerings encompass various interventions such as gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and multiple therapeutic modalities including ABA therapy, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company operates centers in several locations across California, including Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.

Abivax is a clinical-stage biotechnology company based in France that develops therapeutics aimed at harnessing the body's natural immune response to treat autoimmune diseases, viral infections, and cancer. The company is currently evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Abivax focuses on addressing significant unmet medical needs in chronic inflammatory diseases, particularly inflammatory bowel diseases, which include ulcerative colitis and Crohn's disease. Through its innovative drug development platforms, Abivax aims to provide novel and effective treatment options for patients suffering from these conditions.

Intus Care, Inc. is a healthcare analytics platform focused on improving patient care and reducing hospitalizations for vulnerable and complex patients. Founded in 2018 and based in North Providence, Rhode Island, the company connects home care providers to patients through an application that tracks provider efficiency via electronic visit verification. Utilizing machine learning, the platform predicts hospital readmissions and identifies patients at high risk for hospitalizations. It also facilitates automatic patient risk grouping, enables care coordination teams to receive notifications about changes in patient health status, and supports the development of data-driven interventions and care plans. By synthesizing financial, clinical, and administrative data, Intus Care helps organizations such as nursing homes, PACE programs, and home care agencies visualize healthcare trends, ultimately aiming to deliver cost-effective healthcare solutions.

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

Innervace is a regenerative therapy company based in Philadelphia, Pennsylvania, focused on developing implantable tissue-engineered brain pathways to address neurodegenerative disorders. The company specializes in creating anatomically inspired living scaffolds designed for brain pathway reconstruction. Its lead clinical product is a tissue-engineered nigrostriatal pathway, which aims to replicate the lost pathway in patients with Parkinson's disease. By concentrating on the reconstruction of brain pathways rather than merely alleviating symptoms temporarily, Innervace offers innovative solutions that aim to improve the quality of life for individuals affected by these conditions. Established in 2018, the company is dedicated to advancing its products from development to commercialization.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

We believe that all patients deserve the most innovative, open surgical treatment options so they can live their fullest lives. We’re on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The Symani® Surgical System is a first-of-its kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery to restore quality of life for more patients.

Humanity Health is a platform dedicated to supporting underrepresented leaders in healthcare and life sciences by facilitating career advancement and talent acquisition. The company employs a personalized service model to provide women and people of color with access to career-accelerating opportunities and valuable introductions. It also assists employer partners in identifying, engaging, and recruiting diverse healthcare talent, leading to more inclusive hiring outcomes. The Humanity Talent Network (HTN), a private membership network, serves to amplify and connect experienced underrepresented professionals, helping them excel in competitive executive roles, board positions, and entrepreneurial opportunities. Through its proprietary screening technology and leadership development programs, Humanity Health aims to transform the landscape of healthcare recruitment and promote diversity within the industry.

Apertura Gene Therapy is a biotechnology company focused on developing innovative genetic medicines aimed at treating intractable diseases with limited treatment options. The company specializes in the engineering of adeno-associated virus (AAV) capsids that effectively bind to the human Transferrin Receptor 1 (TfR1), facilitating intravenous delivery of therapeutics through receptor-mediated transcytosis across the blood-brain barrier. This approach allows for broad penetration of the central nervous system. In addition to AAV capsids, Apertura also develops regulatory elements and therapeutic payloads to address challenges related to cellular access, gene expression, pre-existing immunity, and manufacturability. By collaborating with corporate and academic partners, Apertura is committed to advancing gene therapy and improving outcomes for patients suffering from debilitating diseases.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, established in 2017. The company specializes in researching and developing non-hormonal birth control options for men, utilizing homeodomain-interacting protein kinase 4 (HIPK4). Additionally, Vibliome focuses on creating small molecule kinase inhibitors aimed at treating various cancers and inflammatory diseases. Their innovative approach involves a systematic methodology that enables the development of inhibitors with unique selectivity profiles, leveraging the extensive array of over 500 kinases present in the human genome. By analyzing the design of Type II inhibitors, Vibliome aims to lock kinase targets in an inactive conformation, facilitating the identification of unique similarities and differences between kinases, which supports the advancement of therapeutics for cancer and other chronic conditions.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, established in 2007 and headquartered in Cerritos, California, with additional facilities in Arizona and Nevada. The organization provides a wide range of services aimed at cancer awareness, prevention, diagnosis, and treatment. Its offerings include chemotherapy education, comprehensive lab testing, pain management, financial and dietary counseling, and an in-house pharmacy. The institute also features an infusion center, support groups, and conducts clinical trials, ensuring patients have access to the latest treatments. Notably, it operates the Hope, Health, and Healing Center, which focuses on alternative and holistic therapies alongside conventional chemotherapy. With over 80 physicians and advanced practice providers across more than 50 clinic locations, the Oncology Institute serves over 1 million patients, delivering evidence-based cancer care in community settings.

Lark is a developer of a virtual chronic disease prevention and management platform that offers personalized support and counseling to users. Utilizing advanced artificial intelligence alongside human coaches and connected devices, Lark provides real-time, 24/7 assistance, helping individuals make healthier choices and manage chronic conditions effectively. The company has established CDC-recognized programs, including its Diabetes Prevention Program, Wellness Program, Diabetes Care Program, and Hypertension Program, which collectively serve 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in 11 peer-reviewed journals and analyst reports. Founded in 2011 by Julia Hu and Jeff Zira, Lark is headquartered in Mountain View, California.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

GeneDx is dedicated to providing personalized health insights that enhance diagnosis, treatment, and drug discovery. By integrating extensive genomic expertise with advanced data interpretation capabilities, the company aims to establish precision medicine as a standard in healthcare. GeneDx specializes in exome and genome testing and interpretation, leveraging one of the largest rare disease data sets available. Its operations are divided into two segments: GeneDx, which generates the majority of revenue, and Legacy Sema4 diagnostics. Through these efforts, GeneDx is positioned to significantly impact health outcomes by using genomic and large-scale clinical information.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

Talkspace is a behavioral healthcare company that provides online therapy services through its technology platform, connecting users with licensed therapists, psychologists, and psychiatrists. The platform allows for confidential communication and unlimited messaging therapy, enabling individuals to seek help for various mental health conditions without the need for in-person appointments. This approach caters to those who may find it difficult to open up in traditional therapy settings or who face financial barriers to accessing care. Talkspace serves a diverse clientele, including health plans, enterprises, and individual subscribers, generating revenue primarily from payor and direct-to-enterprise clients. The company focuses on delivering quality mental health support, aiming to improve the well-being of its users globally.

Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Established in 2018 and located in Menlo Park, California, the company employs advanced platforms such as engineered partial agonists and orthogonal cell therapies. Its Synthekine Platform utilizes surrogate agonists instead of traditional mutant cytokines, allowing for the creation of therapeutics that enhance efficacy while minimizing side effects. The product pipeline includes STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy targeting CD-19, along with STK-012, which consists of partial agonists of IL-2. Synthekine aims to revolutionize treatment paradigms by harnessing the principles of cytokine partial agonism and immunological specificity, leading to novel immunotherapies that improve patient outcomes.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.

GH Research PLC is a clinical-stage biopharmaceutical company that aims to transform the treatment of psychiatric and neurological disorders. The company is primarily focused on developing novel and proprietary therapies based on 5-MeO-DMT, a compound known as Mebufotenin, to address the needs of patients suffering from Treatment-Resistant Depression (TRD). Through its innovative approach, GH Research seeks to provide new therapeutic options for individuals who have not responded to conventional treatments.

Crossover Health, Inc. provides comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010, the company is headquartered in Aliso Viejo, California, with health centers located in various regions, including Silicon Valley. Crossover Health offers a wide range of services, including primary care, urgent care, chronic disease management, preventive care, health risk assessments, and health education. Additionally, it provides ancillary services such as physical therapy, chiropractic care, acupuncture, and care coordination, along with health analytics and remote care options. The company's focus is on creating a positive employee care experience that promotes a healthy and motivated workforce while delivering financial benefits to organizations.

Twill is a healthcare platform focused on enhancing mental and physical wellness. It offers a software solution that employs web and mobile technology to evaluate users' happiness through both subjective and objective assessments. The platform includes various programs and games designed to promote healthier mindsets. By addressing issues such as stress, depression, anxiety, and social isolation, Twill aims to support individuals, employers, and care delivery systems in managing the challenges associated with chronic illness.

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

Nuvalent is a clinical-stage biotechnology company focused on developing targeted therapies for cancer, specifically aimed at clinically validated kinase targets. With a strong foundation in structure-based design, Nuvalent creates small molecules that exhibit high selectivity, aiming to address issues of resistance and minimize side effects associated with conventional treatments. The company's pipeline includes lead programs such as NVL-520 for ROS1-positive non-small cell lung cancer (NSCLC) and NVL-655 for ALK-positive NSCLC, as well as several discovery-stage initiatives. All operations are conducted within the United States, where Nuvalent seeks to enhance treatment options for patients with significant unmet medical needs.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.

Curation Health, LLC is a clinical decision support company that provides a platform designed to enhance value-based care. Established in 2018 and based in Annapolis, Maryland, its platform integrates with electronic health records to deliver actionable risk adjustment insights. This functionality allows healthcare providers to capture accurate clinical opportunities before and after patient visits, ensuring precise documentation and improving performance in various healthcare programs, including Medicare advantage and Medicaid risk programs. By leveraging clinical and quality rules, Curation Health aims to simplify clinical data management and improve patient care, facilitating a seamless transition from fee-for-service to value-based care models.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Ready Responders was founded in 2016 with the mission of giving patients direct access to healthcare professionals in their homes and giving Responders the opportunity to provide care in their communities. Responders travel to patients’ homes to address their physical, mental, and social health needs, utilizing technology to connect with an advanced medical or behavioral health provider, and connecting them with external resources and relationships for ongoing, sustained support. With Ready Responders, patients now have access to quality whole-person care in their homes, 16 hours a day, 365 days a year, and talented individuals are provided the opportunity to work with a rapidly growing, mission-driven company. They are in-network with most major insurance companies in the markets they serve. Ready Responders is backed by leading venture capital firms, including Google Ventures, Founders Fund, Rise of the Rest, and City Lights Capital.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

GeneDx is dedicated to providing personalized health insights that enhance diagnosis, treatment, and drug discovery. By integrating extensive genomic expertise with advanced data interpretation capabilities, the company aims to establish precision medicine as a standard in healthcare. GeneDx specializes in exome and genome testing and interpretation, leveraging one of the largest rare disease data sets available. Its operations are divided into two segments: GeneDx, which generates the majority of revenue, and Legacy Sema4 diagnostics. Through these efforts, GeneDx is positioned to significantly impact health outcomes by using genomic and large-scale clinical information.

Somatus, Inc. is a healthcare company based in McLean, Virginia, specializing in kidney care services. Founded in 2016, it partners with health plans, health systems, nephrology, and primary care groups to offer integrated care for patients with or at risk of developing kidney disease. The company provides a range of services, including home hemodialysis, peritoneal dialysis, in-center hemodialysis, kidney transplantation, and conservative care. Somatus focuses on delaying or preventing the progression of chronic kidney disease and aims to enhance the quality of care through improved coordination and increased utilization of home dialysis and transplantation options. Its approach combines vertically integrated clinical services and technology to optimize patient outcomes.

Meditrina, Inc. is a medical device company based in San Jose, California, specializing in tissue removal solutions for intrauterine pathology. Founded in 2016, the company has developed the Aveta System, an all-in-one solution designed for hysteroscopic diagnostic and therapeutic procedures. This system enables healthcare professionals to perform tasks such as the removal of polyps and fibroids in both office and operating room settings. The Aveta System features wide-angle HD hysteroscopy with electronic image-lock, advanced fluid management for better pressure and fluid control, and a compact design that allows for seamless integration into various medical environments. By providing advanced, convenient, and cost-effective options, Meditrina aims to enhance the care experience for both patients and physicians.

ARTMS is a technology developer focused on transforming the production of diagnostic imaging isotopes. The company has created the QUANTM Irradiation System, which supports decentralized and local production of essential medical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. This innovative technology allows for cost-effective, high-yield production using local hospital-based medical cyclotrons, thereby enabling the nuclear medicine industry to better manage supply chain demands and enhance the availability of critical imaging agents. Through its advancements, ARTMS aims to improve access to important diagnostic tools in healthcare.

Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.

Ready Responders was founded in 2016 with the mission of giving patients direct access to healthcare professionals in their homes and giving Responders the opportunity to provide care in their communities. Responders travel to patients’ homes to address their physical, mental, and social health needs, utilizing technology to connect with an advanced medical or behavioral health provider, and connecting them with external resources and relationships for ongoing, sustained support. With Ready Responders, patients now have access to quality whole-person care in their homes, 16 hours a day, 365 days a year, and talented individuals are provided the opportunity to work with a rapidly growing, mission-driven company. They are in-network with most major insurance companies in the markets they serve. Ready Responders is backed by leading venture capital firms, including Google Ventures, Founders Fund, Rise of the Rest, and City Lights Capital.

Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.

Farapulse commercialize an innovative collection of catheter-based tools used to treat atrial fibrillation. Farapulse are working to make atrial fibrillation ablation safer, faster, more accessible, and less expensive for millions of people.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Contessa, based in Nashville, specializes in Home Recovery Care, a model designed to deliver inpatient hospital care directly in patients' homes. Founded in 2015, the company offers a comprehensive range of services, including acute care, post-acute care, and surgical procedures, supported by its proprietary health informatics platform. This innovative approach allows health systems to enhance their care delivery by treating patients outside of traditional hospital settings, ultimately leading to improved patient outcomes and experiences. Contessa's solutions provide significant cost savings for health plans, enabling a more efficient and effective healthcare model.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

Stelexis Therapeutics, LLC is engaged in the research and development of innovative therapies targeting pre-cancerous stem cells. Founded in 2017 and based in New York, the company utilizes a proprietary drug discovery platform to identify pre-cancerous stem and progenitor cells that contribute to the development of primary and recurrent tumors. Its focus is on developing cancer treatments that specifically target pre-cancerous events associated with hematopoietic malignancies, such as acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors. By addressing these early-stage cancer cells, Stelexis Therapeutics aims to improve therapeutic interventions and reduce the risk of relapse in patients.

The University of North Carolina at Chapel Hill and Deerfield Management have entered into a partnership to create Pinnacle Hill, a company seeking to discover new medicines to address the significant unmet medical needs of their times.Deerfield will invest up to $65 million of targeted funding through Pinnacle Hill, as well as providing significant drug development expertise to advance promising therapeutic research at UNC-Chapel Hill.

Poseidon Innovation is a provider of advance disease curing therapeutics.The company's services weather risky early-stage processes and expedite the drug development cycle, enabling patients to receive treatment faster.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

ReMed provides rehabilitation services, neurobehavioral services, and supported living for people with mild, moderate, and severe brain injuries. They offer residential, outpatient, and home and community-based treatment.

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with debilitating diseases and significant unmet medical needs. The company has a diverse pipeline of product candidates, primarily targeting autoinflammatory and autoimmune conditions. Its clinical-stage candidates include Rilonacept, currently in Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, which is undergoing Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Additionally, Kiniksa is developing KPL-404, a preclinical monoclonal antibody aimed at modulating T-cell-dependent and B-cell-mediated immunity. The company also has a collaboration with Kite Pharma to explore the combination of Mavrilimumab and Yescarta for patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and based in Hamilton, Bermuda, Kiniksa Pharmaceuticals employs a disciplined approach to identify and advance product candidates with strong biological rationales.

Concert Genetics, Inc. is a healthcare information technology company based in Franklin, Tennessee, that specializes in providing software and analytical tools to simplify and unify genetic testing processes for various stakeholders, including hospitals, health systems, patients, clinicians, health plans, laboratories, and regulatory organizations in the United States. The company focuses on enhancing the efficiency of genetic test selection, ordering, payment, and management operations. Its offerings include solutions for claim-to-test matching, medical policy compliance, and laboratory contracting support for health plans, as well as utilization management and health plan policy lookup for hospitals. Additionally, Concert Genetics provides business intelligence reports for laboratories and resources for clinicians, including genetic test searches. The Concert Genetics Benefit Program further enables health plans to facilitate access to clinically appropriate genetic testing while improving payment integrity. Founded in 2010 and originally known as NextGxDx Inc., the company rebranded in 2017 and has established a strategic partnership with Trapelo Health.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.

Operator of a patient-centered healthcare organization intended to expand access to emergency medical care. The company's network of emergency rooms are featured diagnostic radiology equipment and on-site laboratories, enabling the patients to access acuity care with significantly reduced wait times and physicians on-site.

Operator of a patient-centered healthcare organization intended to expand access to emergency medical care. The company's network of emergency rooms are featured diagnostic radiology equipment and on-site laboratories, enabling the patients to access acuity care with significantly reduced wait times and physicians on-site.

Farapulse commercialize an innovative collection of catheter-based tools used to treat atrial fibrillation. Farapulse are working to make atrial fibrillation ablation safer, faster, more accessible, and less expensive for millions of people.

Proteon Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with renal and vascular diseases. Based in Waltham, Massachusetts, the company was founded in 2001 and has a strong emphasis on addressing the medical needs of these patient populations. Its lead product candidate, vonapanitase, is designed to improve hemodialysis vascular access outcomes and has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Additionally, the company is exploring vonapanitase in a Phase I clinical trial targeting peripheral artery disease. Proteon Therapeutics leverages a unique understanding of tissue remodeling to advance its pipeline of proprietary therapeutics, including another candidate aimed at enhancing blood flow following vascular surgery procedures.

Elutia is a commercial-stage regenerative medicine company dedicated to developing innovative products aimed at enhancing patient outcomes during surgical procedures, particularly for those receiving implantable medical devices. The company focuses on several key areas, including Device Protection, Women's Health, and Cardiovascular health, with the Women's Health segment generating the highest revenue. Utilizing proprietary tissue processing platforms, Elutia has created a range of advanced regenerative medical products that closely resemble natural biological materials. These products are designed to address unmet clinical needs by promoting healthy tissue formation and minimizing complications commonly associated with medical device implants, such as scar tissue formation and capsular contraction.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.

Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Aprecia Pharmaceuticals, LLC is a pharmaceutical company that specializes in the development and manufacturing of advanced drug delivery systems and products. Founded in 2003, the company operates from its headquarters in Blue Ash, Ohio, with manufacturing facilities in East Windsor and New Jersey. Aprecia is known for its proprietary ZipDose technology, which facilitates the creation of orodispersible formulations, enabling the delivery of medications in a convenient and effective manner. The company's product offerings include SPRITAM, a medication for treating various types of seizures, as well as CustomRelease, which allows for tailored time release profiles, and NanoDose, designed for submilligram dosing. Aprecia also provides ImplantaDose for post-surgical management of infections and pain, along with solutions for the sequential release of biomimetic proteins and peptides.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Hallux is a privately held clinical-stage pharmaceutical company that develops a new topical dosage form and route of administration for treating onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well-tolerated. The company’s technology delivers high concentrations of the gold standard antifungal terbinafine directly and selectively to the site of infection without introducing it systemically, where it can affect the liver and interact with other drugs that patients may be taking. It was founded in 2012 and is headquartered in Laguna Hills, California.

American Addiction Centers (AAC) is a prominent provider of substance abuse and mental health services in the United States, with a network of rehabilitation facilities across several states, including New Jersey, Florida, and California. Founded in 2007 by Michael Cartwright, a mental health practitioner with extensive experience, AAC focuses on addressing co-occurring mental disorders and addiction through research-driven methodologies. The company has rapidly expanded its reach and capabilities, acquiring treatment centers and enhancing its digital marketing presence to connect with patients seeking help. AAC employs an interventional approach that involves family and community support, which has proven effective in encouraging individuals to seek treatment. Additionally, AAC has dedicated efforts towards veteran care, responding to the unique challenges faced by this population. The organization also emphasizes awareness-raising initiatives, such as its documentary series "Far From Finished," which highlights recovery stories to inspire others. Overall, AAC is committed to providing compassionate, high-quality care to help individuals overcome addiction and mental health issues, with ongoing plans for growth and service improvement.

Akari Therapeutics is a clinical-stage biopharmaceutical company based in London, specializing in the development of treatments for rare and orphan autoimmune and inflammatory diseases. The company primarily focuses on therapies that target the complement component 5 (C5) and leukotriene B4 (LTB4) pathways, which are central to disease progression in various conditions. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor that also inhibits LTB4 activity, currently undergoing Phase II clinical trials for several indications, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, bullous pemphigoid, and thrombotic microangiopathy. Akari's research encompasses a range of therapeutic areas, aiming to address significant unmet medical needs in these complex diseases.

RedBrick Health, based in Minneapolis and established in 2006, focuses on addressing the rising costs of healthcare by offering innovative solutions that promote healthier behaviors among consumers. The company provides technology-enabled enterprise services that facilitate informed healthcare decisions through a combination of behavior-based health financing, personalized programs, and independent advocacy. By leveraging advanced behavior design and insights from data analytics, RedBrick Health aims to enhance consumer engagement and improve the effectiveness of population health and well-being initiatives for employers, health plans, health systems, and accountable care organizations. Through these efforts, RedBrick Health seeks to create better consumer health outcomes and support its clients in managing healthcare costs more effectively.

Aralez Pharmaceuticals operates as a pharmaceutical company. The Company focuses on acquiring, developing, and commercializing products primarily in cardiovascular, pain, and other specialty areas. Aralez Pharmaceuticals serves customers worldwide.

Assertio Holdings, Inc. is a specialty pharmaceutical company based in Lake Forest, Illinois, focused on developing and commercializing products for pain management and central nervous system conditions. Founded in 1995, the company markets several FDA-approved products, including CAMBIA, a non-steroidal anti-inflammatory drug for treating migraines; Zipsor, which provides relief for mild to moderate acute pain; and Gralise, a once-daily gabapentin formulation for managing postherpetic neuralgia. Assertio also offers NUCYNTA ER and NUCYNTA IR, extended-release and immediate-release formulations of tapentadol, respectively, for neuropathic pain and moderate to severe acute pain. The company has established collaborations, including a licensing agreement with Ironwood Pharmaceuticals, further enhancing its position in the specialty pharmaceutical market.